Imunon annual ebitda margin
2017
2018
2019
2020
2021
2022
Imunon EBITDA Margin Growth & History (IMNN)
Imunon's ebitda margin was −4,837.99% for fiscal 2022.
View full Imunon company overviewImunon annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −4,837.99% | −777.13 pp |
| 2021 | 2021-12-31 | −4,060.85% | −511.88 pp |
| 2020 | 2020-12-31 | −3,548.98% | +419.78 pp |
| 2019 | 2019-12-31 | −3,968.76% | +172.88 pp |
| 2018 | 2018-12-31 | −4,141.64% | −558.55 pp |
| 2017 | 2017-12-31 | −3,583.08% | — |
Imunon quarterly ebitda margin
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q3.15
Q4.15
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | −5,366.94% | −1102.39 pp |
| Q3 2022 | 2022-09-30 | −4,802.37% | −880.26 pp |
| Q2 2022 | 2022-06-30 | −4,648.24% | −745.69 pp |
| Q1 2022 | 2022-03-31 | −4,534.39% | −380.19 pp |
| Q4 2021 | 2021-12-31 | −4,264.55% | −565.03 pp |
| Q3 2021 | 2021-09-30 | −3,922.11% | −748.89 pp |
| Q2 2021 | 2021-06-30 | −3,902.56% | −241.49 pp |
| Q1 2021 | 2021-03-31 | −4,154.20% | −492.10 pp |
| Q4 2020 | 2020-12-31 | −3,699.52% | −48.95 pp |
| Q3 2020 | 2020-09-30 | −3,173.22% | +996.65 pp |
| Q2 2020 | 2020-06-30 | −3,661.07% | +656.16 pp |
| Q1 2020 | 2020-03-31 | −3,662.10% | +75.27 pp |
| Q4 2019 | 2019-12-31 | −3,650.57% | +73.45 pp |
| Q3 2019 | 2019-09-30 | −4,169.87% | −1021.83 pp |
| Q2 2019 | 2019-06-30 | −4,317.23% | +2022.12 pp |
| Q1 2019 | 2019-03-31 | −3,737.37% | −382.23 pp |
| Q4 2018 | 2018-12-31 | −3,724.02% | +125.92 pp |
| Q3 2018 | 2018-09-30 | −3,148.04% | +234.02 pp |
| Q2 2018 | 2018-06-30 | −6,339.35% | −2957.29 pp |
| Q1 2018 | 2018-03-31 | −3,355.15% | +363.15 pp |
| Q4 2017 | 2017-12-31 | −3,849.93% | — |
| Q3 2017 | 2017-09-30 | −3,382.05% | — |
| Q2 2017 | 2017-06-30 | −3,382.05% | — |
| Q1 2017 | 2017-03-31 | −3,718.30% | — |
| Q4 2015 | 2015-12-31 | −3,881.24% | +1178.15 pp |
| Q3 2015 | 2015-09-30 | −3,305.79% | +1959.34 pp |
| Q1 2015 | 2015-03-31 | −5,042.70% | −950.98 pp |
| Q4 2014 | 2014-12-31 | −5,059.39% | — |
| Q3 2014 | 2014-09-30 | −5,265.13% | — |
| Q2 2014 | 2014-06-30 | −5,060.46% | — |
| Q1 2014 | 2014-03-31 | −4,091.72% | — |
Imunon ebitda margin trends
Over the last five fiscal years, Imunon's ebitda margin decreased from −3,583.08% to −4,837.99%, a change of −1254.90 percentage points. The latest reported quarter, Q4 2022, shows −5,366.94%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...